Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – What’s Next?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s share price gapped up before the market opened on Tuesday. The stock had previously closed at $15.36, but opened at $15.89. Ascentage Pharma Group International shares last traded at $15.49, with a volume of 983 shares changing hands.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on AAPG. JPMorgan Chase & Co. reduced their price objective on Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating on the stock in a research note on Thursday, October 8th. Citigroup started coverage on shares of Ascentage Pharma Group International in a research report on Wednesday, October 14th. They set a “buy” rating and a $46.00 price target for the company. William Blair began coverage on Ascentage Pharma Group International in a research report on Friday, October 16th. They set an “outperform” rating for the company. Citizens Jmp started coverage on Ascentage Pharma Group International in a report on Tuesday, October 13th. They set a “market outperform” rating and a $35.00 target price on the stock. Finally, BTIG Research reaffirmed a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Friday, August 21st. Two investment analysts have rated the stock with a Strong Buy rating and eleven have given a Buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $43.44.

Ascentage Pharma Group International Trading Up 0.5%

The company has a current ratio of 1.22, a quick ratio of 1.18 and a debt-to-equity ratio of 1.09. The business has a 50-day moving average price of $15.52 and a 200-day moving average price of $19.83.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The business had revenue of $22.24 million during the quarter. Equities research analysts predict that Ascentage Pharma Group International – Unsponsored ADR will post -2.43 EPS for the current fiscal year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases. Its research focuses on therapies that target mechanisms involved in programmed cell death, or apoptosis, to help prevent cancer cells from surviving and multiplying. The company’s two approved oncology drugs in China are olverembatinib, used to treat certain forms of leukemia, and lisaftoclax (APG-2575), a BCL-2 inhibitor approved for certain patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.